Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells

British Journal of Anaesthesia

Volumn 89, Issue 4, 2002, Pages 571-579

  Girard, T ^a   Treves, S ^a   Censier, K ^a   Mueller, C R ^b   Zorzato, F ^a,c   Urwyler, A ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

Anaesthesia; Anaesthetics volatile, halothane; Ions, calcium; Muscle, skeletal myoblasts

Indexed keywords

CAFFEINE; CALCIUM ION; FURA 2 ACETOXYMETHYL ESTER; HALOTHANE; INHALATION ANESTHETIC AGENT; RYANODINE RECEPTOR; SUXAMETHONIUM;

ADOLESCENT; ADULT; ARTICLE; CALCIUM CELL LEVEL; CELL CULTURE; CLINICAL PROTOCOL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG INDUCED DISEASE; EUROPE; FLUORESCENCE MICROSCOPY; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTRACELLULAR MEMBRANE; LETHALITY; MAJOR CLINICAL STUDY; MALIGNANT HYPERTHERMIA; MEASUREMENT; MEDICAL SOCIETY; MUSCLE BIOPSY; MUSCLE CELL; MUSCLE FIBRIL; PHENOTYPE; PRIORITY JOURNAL; SCHOOL CHILD; SKELETAL MUSCLE;

EID: 0036794325     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/aef237     Document Type: Article

References (22)

1. Denborough M. Anaesthetic deaths in a family. Lancet 1960; 2: 45
2. Denborough M. Malignant hyperthermia. Lancet 1998; 352: 1131-6
3. Gronert G, Antonigni J, Pessah I. Malignant hyperthermia. In: Miller R, ed. Anesthesia. New York: Churchill Livingstone, 2000; 1033-52
4. Bendixen D, Skovgaard LT, Ording H. Analysis of anaesthesia in patients suspected to be susceptible to malignant hyperthermia before diagnostic in vitro contracture test. Acta Anaesthesiol Scand 1997; 41: 480-4
5. Puschel K, Schubert-Thiele I, Hirth L, Benkmann HG, Brinkmann B. Malignant hyperthermia during the 13th general anaesthesia. Anaesthesist 1978; 27: 488-91
6. Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-9
7. MacLennan DH, Phillips MS. Malignant hyperthermia. Science 1992; 256: 789-94
8. Ording H. Diagnosis of susceptibility to malignant hyperthermia in man. Br J Anaesth 1988; 60: 287-302
9. European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984; 56: 1267-9
10. Iaizzo PA, Klein W, Lehmann-Horn F. Fura-2 detected myoplasmic calcium and its correlation with contracture force in skeletal muscle from normal and malignant hyperthermia susceptible pigs. Pflugers Arch 1988; 411: 648-53
11. Mickelson JR, Gallant EM, Litterer LA, et al. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J Biol Chem 1988; 263: 9310-5
12. McCarthy TV, Healy JM, Heffron JJ, et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q 12-13.2. Nature 1990; 343: 562-4
13. Fujii J, Otsu K, Zorzato F, et al. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991; 253: 448-51
14. Manning BM, Quane KA, Ording H, et al. Identification of novel mutations in the ryanodine-receptor gene (ryrI) in malignant hyperthermia: Genotype-phenotype correlation. Am J Hum Genet 1998; 62: 599-609
15. Robinson RL, Monnier N, Wolz W, et al. A genome wide search for susceptibility loci in three european malignant hyperthermia pedigrees. Hum Mol Genet 1997; 6: 953-61
16. Jurkat-Rott K, McCarthy T, Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 2000; 23: 4-17
17. Censier K, Urwyler A, Zorzato F, Treves S. Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect of overexpression of recombinant wild-type and arg163cys mutated ryanodine receptors. J Clin Invest 1998; 101: 1233-42
18. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-50
19. Girard T, Urwyler A, Censier K, et al. Genotype-phenotype comparison of the swiss malignant hyperthermia population. Hum Mutat 2001; 18: 357-8
20. Ording H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant mh and unrelated low-risk subjects. The european malignant hyperthermia group. Acta Anaesthesiol Scand 1997; 41: 955-66
21. 2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. J Biol Chem 1997; 272: 26332-9
22. Urwyler A, Deufel T, McCarthy T, West S. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001; 86: 283-7